摘要
目的:探讨左炔诺孕酮宫内释放系统(LNG-IUS;商品名:曼月乐)治疗子宫腺肌症所致中、重度痛经的临床疗效。方法:对子宫腺肌症所致中、重度痛经的患者37例,于月经期的第5～7天放置LNG-IUS,行自身前后对照。比较放置LNG-IUS前及放置后3、6、12个月时痛经评分,B超测量子宫大小,同时分别测定血清CA125、月经第3天血清雌二醇、卵泡刺激素(FSH)、黄体生成素(LH)水平。结果:放置LNG-IUS后12个月,37例痛经患者的VAS评分分别由置环前的(73±12)分后下降为置环后3、6、12月的(22±16)、(14±18)、(10±9)分,经量评分分别由置环前的(115.6±56.2)下降为置环后3、6、12月的(56.5±21.3)、(38.7±18.9)、(18.7±6.3),差异均有统计学意义(P<0.01)。置环前子宫内膜厚度、血清CA125分别由(8.0±1.8)和(37.8±14.6)下降为6、12月的(4.3±1.9)、(4.1±1.5)和(30.6±14.6)、(21.9±16.3),差异均有统计学意义(P<0.05)。29例(78.38%,29/37)患者对治疗的综合效果表示非常满意或满意。结论:LNG-IUS是手术之外治疗子宫腺肌症的有效且安全的方法。
Objective：To evaluate the efficacy and safety of a levonorgestrel releasing intrauterine system（LNG-IUS） in the treatment of dysmenorrheal associated with adenomyosis.Methods：Thirty seven patients with adenomyosis were followed up in 3,6,12 months after treating with LNG-IUS.The menstrual blood volume,dysmenorrheal,size of ulteri and endometrial thickness were observed and evaluated.Results：There were significant differences between mean VAS scores changes of dysmenorrheal and dyspareunia at baseline and 12 months follow up,those of dysmenorrheal dropping from（73±12）to（22±16）,（14±18）,（10±9）,those of dyspareunia dropping from（115.6±56.2） to（56.5±21.3）,（38.7±18.9）,（18.7±6.3） respectively.Endometrial thickness and CA125 dropping from significantly from（8.0±1.8）and（37.8±14.6） to（4.3±1.9）,（4.1±1.5）and（30.6±14.6）,（21.9±16.3）,Overall 29 women（78.38%）were very satisfied or satisfied with the one year treatment.Conclusion：LING-IUS is an effective and safe therapy for adenomyosis.
出处
《中国妇幼保健》
CAS
北大核心
2011年第14期2205-2207,共3页
Maternal and Child Health Care of China
关键词
左炔诺孕酮
子宫腺肌症
痛经
Levonorgestrel
Endometriosis
Dysmenorrhea
